As government funding dries up, Pfizer expects to charge private payers $110+ for Covid-19 vaccine
For months, companies behind Covid-19 vaccines and therapies have been talking about transitioning to a private commercial market once the government funding dries up. As its purchase program with the US comes to an end, Pfizer is putting a dollar figure to the discussion.
Pfizer plans to charge $110 to $130 for its BioNTech-partnered Covid-19 shot, almost quadrupling the price, Angela Lukin, global primary care & US president, told Reuters and Wall Street Journal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.